HEALTH TECHNOLOGY

Dialyze Direct Partners with CommuniCare Health to Provide On-Site Dialysis

Dialyze Direct | July 28, 2022 | Read time : 45:49 min

Dialyze Direct

Dialyze Direct, the nation’s leading provider of home hemodialysis services in Skilled Nursing Facilities. announced it has partnered with CommuniCare Family of Companies, one of the nation’s largest post-acute care providers, to conduct onsite hemodialysis services at its facilities around the U.S.

Founded in 1984 on the philosophy of “Serving with Pride,” CommuniCare’s standard of excellence, which focuses on patient care and quality of life, mirrors Dialyze Direct’s mission to change the dialysis industry by pioneering customized, gentler care proven to positively impact patients’ prognoses and quality of life. Dialyze Direct’s continued growth with like-minded healthcare providers has further solidified the company’s position as the foremost home hemodialysis provider to SNFs in the United States.

The ultimate goal of healthcare is to provide services that benefit our clients but also to ensure those services save or significantly prolong lives. As a result, we approach partnerships with the understanding that both parties share a common patient-first philosophy. We are pleased to bring our onsite dialysis offerings to CommuniCare’s facilities and join forces with a fellow provider that also views patient comfort and care as the cornerstone of their business model.”

Dialyze Direct’s Chairman and Co-Founder Henry Kauftheil

Dialyze Direct recently announced its acquisition of Chicago-based RenPro Renal Services, which provided dialysis services to patients in SNFs in Illinois, Indiana, Ohio and Kentucky. Earlier this year, the company completed its acquisition of Compass Home Dialysis, a regional SNF dialysis provider in Pennsylvania, and at the end of 2021, the company acquired Renew Dialysis, a regional SNF dialysis provider in Ohio and Virginia.

“Providing our residents with a better quality of life is what we strive for at CommuniCare,” said Ronald Wilheim, President of CommuniCare. “We are proud to partner with Dialyze Direct and that through this partnership we have another opportunity to raise the bar and innovate our level of care.”

Dialyze Direct now offers onsite dialysis services in more than 170 SNFs in Florida, Illinois, Indiana, Kentucky, Maryland, Missouri, New Jersey, New York, Ohio, Pennsylvania, Tennessee, Texas, Virginia, and West Virginia.

About Dialyze Direct
Founded in 2015, Dialyze Direct is a leading kidney care innovation company that seeks breakthrough solutions for patients suffering from kidney disease. With a mission to build the next generation of kidney care, Dialyze Direct leverages its leading nephrology specialists to develop new methods and technology to evolve the treatment options nephrologists have at their disposal. Dialyze Direct pioneered significant changes to the existing treatment model for dialysis patients in skilled nursing facilities (SNFs), in which many of the most medically challenging subsets of dialysis patients reside, and has grown to become the nation’s largest provider of home dialysis in the SNF setting. Dialyze Direct’s innovative staff-assisted home hemodialysis treatment model entails a gentler, personalized treatment plan comprised of meticulously crafted protocols designed to tackle the unique fluid management challenges of geriatric dialysis patients, resulting in increased overall patient health and reduced hospitalizations while substantially decreasing costs for payors. Dialyze Direct currently operates in 13 states with new operations launching soon in additional states.

About CommuniCare Health Services
CommuniCare Health Services was founded in 1984 and is headquartered in Cincinnati, Ohio. The company currently operates more than 110 healthcare and rehabilitation centers in seven states.

Our centers focus on patient-centered care plans and provide specialized programing in cardiac, pulmonology, memory care & dementia, amputee and behavioral health. Our expert physicians and nurses provide care for the most medically complex residents. 

Spotlight

That’s why CommScope networks enable connected care from core to edge.

Spotlight

That’s why CommScope networks enable connected care from core to edge.

Related News

FUTURE OF HEALTHCARE

Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence

Anumana, Inc. | July 14, 2022

Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial intelligence powered software solutions that will detect hidden cardiovascular conditions. The collaboration will drive development and delivery of electrocardiogram (ECG) AI algorithms to help physicians accelerate detection and intervention for patients with previously undetected life-threatening heart disease. The ECG AI algorithm is still in development and not yet FDA authorized for commercial clinical use. The collaboration will support Anumana’s efforts to implement AI-enabled diagnostic software that can detect signals from ECGs that humans cannot interpret. The collaboration will initially focus on cardiovascular diseases. Working with its expert partners from Mayo Clinic, Anumana will deploy novel solutions that use AI to analyze an ECG, a widely available, painless test that records the heart’s electrical signals to identify undiagnosed left ventricular dysfunction, or a weak heart pump, which can lead to heart failure. The AI will also screen for atherosclerotic cardiovascular disease, which can lead to heart attack and stroke. In addition, an evidence-based, digital point-of-care solution will be developed to guide in optimizing guideline-directed medical therapies with the aim to lower risk for potentially avoidable hospitalizations and cardiovascular death. “Anumana technology is designed to help physicians identify patients who are at maximum risk of heart failure, long before they develop symptoms. Bringing together premier global organizations will allow us to expand access to best-in-class, AI-powered digital tools to benefit patients through earlier detection and intervention, when and where health care providers need it most.” Murali Aravamudan, CEO of Anumana “Many heart diseases develop for years before signs and symptoms appear, but the first event may be life threatening,” said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Chair of Anumana’s Mayo Clinic Board of Advisors. “AI enables us to uncover hidden signals our bodies transmit to detect otherwise occult heart diseases, potentially years before symptoms appear. This collaboration has the potential to transform the use of a ubiquitous inexpensive test, the ECG, with the aim of democratizing disease detection and helping medical care teams to proactively manage heart disease ahead of time and prevent some clinical events from ever happening.” “Cardiovascular disease is a widespread and multifactorial disease and, in order to mitigate its impact, we must look beyond therapeutic innovation and reimagine how we approach cardiovascular care,” said Victor Bulto, President, Novartis Innovative Medicines US. "Novartis is proud to collaborate with Anumana on innovative and data-driven solutions to better predict the risk of life-threatening heart disease, further driving forward our commitment to improving patient experiences and population health outcomes in this patient population.” The Mayo Clinic Cardiology team, led by Dr. Friedman, pioneered the application of AI in cardiology and developed several algorithms based on millions of ECGs, including a low ejection fraction algorithm that received FDA Breakthrough Device Designation in 2019 and Emergency Use Authorization for COVID-19 in 2020. Further validating the technology, a recent study presented by Mayo Clinic used a modified version of Anumana’s 12-lead ECG algorithm to detect left ventricular dysfunction with single-lead ECGs in smartwatches. These algorithms are licensed to Anumana for development of clinical solutions and have been validated by over 30 peer-reviewed publications, including a first of its kind prospective clinical impact study on low ventricular ejection fraction that was published in Nature Medicine in 2021. These software solutions are currently in development with each algorithm as a candidate for marketing authorization through an FDA De Novo request. About Anumana Anumana, an AI-driven health technology company and a portfolio company of nference and Mayo Clinic Platform, is harnessing industry-leading AI and translational science to decode the electrocardiogram as never before – as a deep predictive tool and biomarker of disease – empowering care providers to help patients early. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and are undergoing rigorous clinical trial validation. Anumana is developing AI-enabled ECG algorithms for real-world physician use, integrating point-of-care applications into existing workflows, thereby reducing costs and enhancing quality of life. Anumana’s AI-enabled tools can diagnose hidden conditions earlier than ever before. Anumana’s algorithms are investigational medical devices and have not yet received regulatory approval or clearance.

Read More

HEALTH TECHNOLOGY

Medtronic announces partnership with BioIntelliSense for exclusive U.S. distribution of multi-parameter wearable

Medtronic plc | September 01, 2022

Medtronic plc a global leader in healthcare technology, announced it has entered into a strategic partnership with BioIntelliSense, a continuous health monitoring and clinical intelligence company, for the exclusive U.S. hospital and 30-day post-acute hospital to home distribution rights of the BioButton® multi-parameter wearable for continuous, connected monitoring. The partnership enables the Medtronic Patient Monitoring business to offer access to a medical grade device that provides continuous vital sign measurements of general care patients in-hospital as well as post-discharge. This supports the simplification of care delivery through workflow automation, enabling proactive clinical intervention, and helping to address the implications of staffing shortages. Terms of the deal were not disclosed. The BioButton medical grade device, measuring up to 1,440 vital sign measurements per day, including skin temperature, respiratory rate at rest, and heart rate at rest, is the exclusive multi-parameter wearable for the Patient Monitoring business. This device, combined with advanced analytics, has the potential to help enable clinicians to better detect early signs of patient deterioration or, conversely, identify stable patients who may be candidates for earlier hospital discharge. The rechargeable BioButton device also has configurable acute and post-acute modes to continuously monitor patients as they transition from higher to lower acuity settings. "Our vision is to empower clinicians and patients with actionable insights to personalize care — anytime, anywhere," said Frank Chan, Ph.D., president of the Patient Monitoring business, which is part of the Medical Surgical Portfolio at Medtronic. "Today, our solutions touch more than 100 million patients annually in hospitals. Through our collaboration with BioIntelliSense, we will support continuous, connected care from in-hospital to home and expand our reach to help more patients in more places than ever before." With staffing shortages projected to reach 3.2 million healthcare workers by 20261, the Patient Monitoring business intends to continue to expand its HealthCast™ portfolio to improve workflow automation so clinicians can focus on what matters most — their patients. The HealthCast™ connectivity gateway helps increase workflow efficiency by connecting unconnected devices to the electronic medical records (EMR) and saves valuable staff time by reducing the burden of manual charting. The HealthCast™ VitalSync™ remote patient monitoring system enables clinicians to receive near real-time trend and alert data on web-enabled devices so they can act on patient deterioration earlier. With the addition of the BioButton multi-parameter wearable to the HealthCast portfolio, Medtronic can help even more general care patients inside and outside of the hospital, furthering our commitment to patient safety. "In partnership with Medtronic, we are poised to accelerate continuous connected care models that offer a new level of clinical surveillance and workflow efficiencies for hospitals that are challenged in today's environment of growing workforce shortages and cost of care management. This advanced remote physiologic monitoring simplifies care delivery to facilitate personalized patient care, clinical workflow automation and proactive clinical interventions." James Mault, M.D., founder and CEO of BioIntelliSense About BioIntelliSense BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring. Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs and physiological biometrics through an effortless patient experience. The medical grade BioButton® devices make remote monitoring and early detection simple. Through the platform's advanced analytics, clinicians have access to high-resolution patient trending and alerting to enable medical grade remote care from in-hospital to home. About the Patient Monitoring business at Medtronic The Patient Monitoring business is committed to transforming the future of health monitoring. Our vision is to empower clinicians and patients with actionable insights to personalize care. Our technologies, including HealthCast™ intelligent patient manager, VitalSync™ remote patient monitoring, Nellcor™ pulse oximetry, Microstream™ capnography, BIS™ brain monitoring, and INVOS™ regional oximetry are always on watch, helping clinicians keep patients safe. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Read More

HEALTH TECHNOLOGY

Zynx Health and LogicStream Health Power Performance Improvement Solutions

Zynx Health | July 13, 2022

Zynx Health, a pioneer and market leader in evidence- and experience-based clinical solutions, announced a strategic partnership with LogicStream Health, a leading clinical data and clinical intelligence firm. The company said the partnership is focused on delivering advanced performance improvement capabilities to health systems across the United States. The two companies have already begun rolling out this joint solution to customers. “As a pioneer in the industry and for more than a quarter of a century, Zynx Health has consistently evolved its solutions to provide best-in-class content, analytics and performance improvement tools to hospitals and health systems,” said Charles Tuchinda, MD, president of Zynx Health. “The integration of LogicStream Health’s sophisticated clinical data and intelligence software with our product portfolio is the next step in advancing the way clinical teams improve patient outcomes by directly measuring and recommending enhancements to the interventions they order.” “LogicStream, since its founding in 2013, has been focused on delivering timely, data-driven insights about areas for improvement and reduced variation in clinical process and workflows to frontline clinical teams. We are excited about joining forces with Zynx Health to help customers achieve meaningful and measurable improvements in clinical, operational and financial performance.” Patrick Yoder, PharmD, CEO of LogicStream About Zynx Health Zynx Health, a market leader in providing evidence- and experience-based clinical improvement solutions since 1996 and part of the Hearst Health network, provides healthcare professionals with vital information and processes that guide care decisions and reduce complexity across the entire patient journey in a way that leads to healthier lives for all. Named the “Best in KLAS” Category Leader for Clinical Decision Support – Care Plans and Order Sets in 2021 and 2022, Zynx is a pioneer and market leader in evidence- and experience-based clinical solutions that help health systems improve patient outcomes, financial outcomes, clinical engagement, and technology performance. With Zynx Health, healthcare organizations exceed industry demands for delivering high-quality care at lower costs under value-based reimbursement models. About LogicStream LogicStream Health, based in Minneapolis, is trusted by a community of high-performing healthcare providers and partners to generate clinical insights from clinical data. The company’s cloud-based clinical data and intelligence platform gathers, normalizes, and connects clinical data. It houses years of experience in its automated processing, advanced analytics, and machine learning. This platform serves as an underpinning for the company’s software-as-a-service (SaaS) clinical insights, data services, and life science products. As a result, customers reduce cost, improve outcomes, improve the supply chain, and accelerate research and development. Customers are generating millions of dollars in ROI from clinical intelligence using LogicStream Health’s platform.

Read More